Savara Inc Stock Price, News & Analysis

Savara Inc. (NASDAQ: SVRA) announced the resignation of Chief Medical Officer Badrul Chowdhury, effective September 9, 2022. The company expressed appreciation for his contributions, particularly in advancing the molgramostim nebulizer solution for autoimmune pulmonary alveolar proteinosis (aPAP). Chowdhury leaves with confidence in the ongoing Phase 3 IMPALA-2 trial. Savara focuses on rare respiratory diseases, with molgramostim being a key product in development, delivered via the investigational eFlow® Nebulizer System.

Savara Inc. (NASDAQ: SVRA) announced its molgramostim received Promising Innovative Medicine (PIM) designation from the UK’s MHRA for treating autoimmune pulmonary alveolar proteinosis (aPAP). This designation enhances molgramostim’s chance for early access under the UK’s Early Access to Medicines Scheme (EAMS), allowing potential patient use 12-18 months prior to formal marketing authorization. Previous recognitions include Fast Track and Breakthrough Therapy designations from the FDA.

Savara Inc. (Nasdaq: SVRA) reported its financial results for Q2 2022, noting a net loss of $9.2 million, or $(0.06) per share, an improvement from the previous year's loss of $10.9 million. Research and development expenses decreased by 11.5% to $6.4 million, attributed to timing in contract research costs. The pivotal Phase 3 IMPALA-2 trial of Molgramostim remains on track for top-line data by the end of Q2 2024. The company holds approximately $142 million in cash, indicating sufficient funding through 2025.

Savara Inc. (NASDAQ: SVRA), a clinical-stage biopharmaceutical company, announced the acceptance of three abstracts for poster presentation at the ERS International Congress 2022, taking place in Barcelona, Spain from September 4-6, 2022. The accepted abstracts focus on the efficacy measures in patients requiring lung lavage, safety of inhaled molgramostim for aPAP, and the choice of DLCO as a primary endpoint in aPAP research. Results will be published in the European Respiratory Journal supplement by November 2022.

Savara Inc. announced that molgramostim has received the Innovation Passport designation from the UK’s MHRA for treating autoimmune pulmonary alveolar proteinosis (aPAP). This designation is a step towards accelerating market access for innovative medicines in the UK. The drug is currently being investigated in the pivotal Phase 3 trial, IMPALA-2, and previously received Fast Track and Breakthrough Therapy designations from the FDA. The designation highlights the urgent need for effective treatments for aPAP, a debilitating condition.

Savara Inc. (NASDAQ: SVRA), a biopharmaceutical company focused on rare respiratory diseases, announced its management team will present at the Jefferies Healthcare Conference on June 8, 2022, at 1:00 pm ET in New York City. A live webcast will be available on the company's website and archived for 90 days. Savara's lead program, molgramostim, is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP) and utilizes the investigational eFlow® Nebulizer System.

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company specializing in rare respiratory diseases, will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 4:00 pm ET. The presentation will be broadcast live and available for 90 days on Savara's website.

Savara's leading program, molgramostim nebulizer solution, is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP) and is delivered via the investigational eFlow® Nebulizer System.

Savara Inc. (Nasdaq: SVRA) reports Q1 2022 net loss of $8.3 million ($(0.05) per share), improved from $10.2 million ($(0.13) per share) in Q1 2021. R&D expenses decreased 25.1% to $5.7 million due to the winding down of a previous program. The cash position stands at $152 million, sufficient to fund operations through 2025, as top line data from the Phase 3 IMPALA-2 trial of molgramostim is expected by the end of Q2 2024. The company emphasizes its strategic direction amidst global uncertainties.

Savara Inc. (NASDAQ: SVRA) announced on April 22, 2022, the grant of inducement awards to two new employees, comprising options to purchase 55,000 shares of common stock. The options have an exercise price of $1.23 per share, the closing price on the grant date. Each option features a 10-year term and vests quarterly based on the employee's continued service. Savara focuses on rare respiratory diseases, with its lead program, molgramostim nebulizer solution, in Phase 3 development for autoimmune pulmonary alveolar proteinosis.